Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185491 | 0.93 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL232374 | 0.93 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL29623515 | 0.93 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL232373 | 0.93 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL1190779 | 0.92 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL1190783 | 0.92 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL1190781 | 0.92 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL1191361 | 0.84 | EGFR (0.58) | EGFRERBB2ERBB4 | |
| SCHEMBL1191357 | 0.84 | EGFR (0.58) | EGFRERBB2ERBB4 | |
| SCHEMBL1191359 | 0.84 | EGFR (0.58) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |